Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 3/2013

01-06-2013 | Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes Mellitus and Osteoporosis

Authors: Robert Sealand, Christie Razavi, Robert A. Adler

Published in: Current Diabetes Reports | Issue 3/2013

Login to get access

Abstract

Diabetes mellitus (particularly type 2) and osteoporosis are two very common disorders, and both are increasing in prevalence. Adolescents with type 1 diabetes mellitus may not reach potential peak bone mass, putting them at greater fracture risk. In adults with type 2 diabetes, fracture risk is increased and is not explained by the bone mineral density measured by dual-energy X-ray absorptiometry, still considered the gold standard predictor of fracture. In this review, we explore potential mechanisms behind the increased fracture risk that occurs in patients with diabetes, even those with increased bone mineral density. One potential link between diabetes and bone is the osteoblast-produced factor, osteocalcin. It remains to be established whether osteocalcin reflects or affects the connection between bone and glucose metabolism. Several other potential mediators of the effects of diabetes on bone are discussed.
Literature
1.
2.
3.
Bonds D, Larson J, Schwartz A, et al. Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study. J Clin Endocrin Metab. 2006;91:3404–10.CrossRef
4.
Strotmeyer E, Cauley J, Schwartz A, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005;165:1612–1617.
5.
• Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27:319–32. This study clearly demonstrates the increased bone density of type 2 diabetes mellitus.PubMedCrossRef
6.
• Nielson CM, Marshall LM, Adams AL, et al. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J Bone Miner Res. 2011;26:496–502. This prospective study of about 6,000 older men found that obesity was not protective of the skeleton. Indeed fracture risk was higher in obese men.PubMedCrossRef
7.
Tanaka S, Kuroda T, Saito M, Shiraki M. Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women. Osteoporos Int. 2013;24:69–76.PubMedCrossRef
8.
Viegas M, Costa C, Lopes A, et al. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications. 2011;25:216–21.PubMedCrossRef
9.
Compston JE, Watts NB, Chapurlat R, et al. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011;124:1043–50.PubMedCrossRef
10.
Prieto-Alhambra D, Premaor MO, Fina Aviles F, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27:294–300.PubMedCrossRef
11.
Premaor MO, Compston JE, Aviles FF, et al. The association between fracture site and obesity in men: a population-based cohort study. J Bone Miner Res epublished 31 January 2013.
12.
de Liefde I, Van der Klift M, de Laet C, et al. Bone mineral density and fracture risk in type 2 diabetes mellitus: the Rotterdam Study. Osteoporosis Int. 2005;16:1713–20.CrossRef
13.
Lipscombe L, Jamal S, Booth G, et al. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care. 2007;30:835–41.PubMedCrossRef
14.
Bonds D, Larson J, Schwartz A, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrin Metab. 2006;9:3404–10.CrossRef
15.
Mendez J, Rojano-Mejia D, Pedraza J, et al. Bone mineral density in postmenopausal Mexican-Mestizo women with normal body mass index, overweight, or obesity. Menopause epublished December 30, 2012.
16.
• Kao W, Kammerer C, Schneider J, et al. Type 2 diabetes is associated with increased bone mineral density in Mexican–American women. Arch Med Res. 2003;34:399–406. In women, obesity does not protect bones from fracture.PubMedCrossRef
17.
Melton LJ, Riggs BL, Leibson C, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab. 2008;93:4804–9.PubMedCrossRef
18.
• Burghardt A, Issever A, Schwartz A, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:5045–55. Using new techniques, the alterations of cortical bone found in type 2 diabetes mellitus may be one explanation for the increased fracture risk.PubMedCrossRef
19.
• Patsch J, Burghardt A, Yap S, et al. Increased cortical porosity in type-2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 2012 10.1002 Epub ahead of print. This study provides information about cortical bone in T1DM.
20.
Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:45–9.PubMedCrossRef
21.
Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1737–44.PubMedCrossRef
22.
Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:3744–50.PubMedCrossRef
23.
Garcia-Hernandez A, Arzate H, Gil-Chavarria I, Rojo R, Moreno-Fierros L. High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone. 2012;50:276–88.PubMedCrossRef
24.
• Booth SL, Centi AM, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013;9:43–55. This review of osteocalcin looks at the potential role of this bone protein in glucose metabolism.
25.
Iglesias P, Arrieta F, Pinera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-Crosslaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol. 2011;75:184–8.CrossRef
26.
Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21:195–214.PubMedCrossRef
27.
Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380–6.PubMedCrossRef
28.
Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1013–9.PubMedCrossRef
29.
Pittas AG, Nelson J, Mitri J, et al. Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program. Diabetes Care. 2012;35:565–73.PubMedCrossRef
30.
Harris SS, Pittas AG, Palermo NJ. A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab. 2012;14:789–94.PubMedCrossRef
31.
Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8:178–84.PubMedCrossRef
32.
• Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012;27:2231–7. This important review of diabetes and fracture risk includes explanation of how the FRAX risk calculator should be viewed in patients with diabetes.PubMedCrossRef
33.
Dunger DB, Acerini CL. IGF-I and diabetes in adolescence. Diabetes Metab. 1999;24:101–7.
34.
Johnson SB, Silverstein J, Rosenbloom A, Carter R, Cunningham W. Assessing daily management in childhood diabetes. Health Psychol. 1986;5:545–64.PubMedCrossRef
35.
Weissberg-Benchell J, Glasgow AM, Tynan WD, et al. J. Adolescent diabetes management and mismanagement. Diabetes Care. 1995;18:77–8.PubMedCrossRef
36.
Albertson AM, Tobelmann RC, Marquart L. Estimated dietary calcium intake and food sources for adolescent females 1980–1992. J Adolesc Health. 1997;20:20–6.PubMedCrossRef
37.
Thrailkill KM. Diabetes care for adolescents. In: Reece EA, Coustan DR, Gabbe SG, editors. Diabetes in women. Philadelphia: Lippincott Williams & Willkins; 2004.
38.
Brown IR, McBain AM, Chalmers J, et al. Sex differences in the relationship of calcium and magnesium excretion to glycaemic control in type 1 diabetes mellitus. Clin Chim Acta. 1999;283:119–28.PubMedCrossRef
39.
40.
Gunczler P, Lanes R, Paz-Martinez V, et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab. 1998;11:413–9.PubMedCrossRef
41.
Pascual J, Argente J, Lopez MB, et al. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int. 1998;62:31–5.PubMedCrossRef
42.
Valerio G, del Puente A, Esposito-del Puente A, et al. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res. 2002;58:266–72.PubMedCrossRef
43.
Saha MT, Sievanen H, Salo MK, et al. Bone mass and structure in adolescents with type 1 diabetes compared to healthy peers. Osteoporos Int. 2009;20:1401–6.PubMedCrossRef
44.
Gunczler P, Lanes R, Paoli M, et al. Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2001;14:525–8.PubMedCrossRef
45.
Salvatoni A, Mancassola G, Biasoli R, et al. Bone mineral density in diabetic children and adolescents: a follow-up study. Bone. 2004;34:900–4.PubMedCrossRef
46.
Hadjidakis DJ, Raptis AE, Sfakianakis M, Mylonakis A, Raptis SA. Bone mineral density of both genders in type 1 diabetes according to bone composition. J Diabetes Complications. 2006;20:302–7.PubMedCrossRef
47.
Hamilton EJ, Rakic V, Davis WA, et al. A five-year prospective study of bone mineral density in men and women with diabetes: The Fremantle Diabetes Study. Acta Diabetol. 2012;49:153–8.PubMedCrossRef
48.
Liu EY, Wactawski-Wende J, Donahue RP, et al. Does Low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care. 2003;26:2365–9.PubMedCrossRef
49.
Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22:1317–28.PubMedCrossRef
50.
Nicodemus KK, Folsom AR. Iowa Women’s Health Study: type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24:1192–7.PubMedCrossRef
51.
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. 2007;18:427–44.PubMedCrossRef
52.
Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004;3:379–89.PubMedCrossRef
53.
Lecka-Czernik B, Gubrij I, Moerman EA, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem. 1999;74:357–71.
54.
Botolin S, McCabe LR. Inhibition of PPAR-Gamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol. 2006;209:967–76.PubMedCrossRef
55.
Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk. J Intern Med. 2000;248:67–76.PubMedCrossRef
56.
• Coe LM, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2011;226:477–83. This study provides insight into how diabetes affects osteoblasts.PubMedCrossRef
57.
Maor G, Karnieli E. The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor. Endocrinology. 1999;140:1841–51.PubMedCrossRef
58.
Nixon AJ, Lillich JT, Burton-Wurster N, et al. Differentiated cellular function in fetal chondrocytes cultured with insulin-like growth factor-I and transforming growth factor-beta. J Orthop Res. 1998;16:531–41.PubMedCrossRef
59.
Wan Y, Chong LW, Evans RM. PPAR-Gamma regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496–503.PubMedCrossRef
60.
Williams JP, Blair HC, McDonald JM, et al. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun. 1997;235:646–51.PubMedCrossRef
61.
Fraser JH, Helfrich MH, Wallace HM, Ralston SH. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone. 1996;19:223–6.PubMedCrossRef
62.
Pater A, Sypniewska, Pilecki O. Biochemical markers of bone cell activity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010;23:81–6.PubMedCrossRef
63.
Hill PA, Tumber A, Meikle MC. Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology. 1997;138:3849–58.PubMedCrossRef
64.
Thomas DM, Udagawa N, Hards DK, et al. Insulin receptor expression in primary and cultured osteoclast-like cells. Bone. 1998;23:181–6.PubMedCrossRef
65.
Conover CA, Lee PD, Riggs BL, Powell DR. Insulin-like growth factor-binding protein-1 expression in cultured human bone cells: regulation by insulin and glucocorticoid. Endocrinology. 1996;137:3295–301.PubMedCrossRef
66.
Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res. 2008;23:1884–91.PubMedCrossRef
67.
Pastor MMC, Lopez-Ibarra PJ, Escobar-Jimenez F, et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int. 2000;11:455–9.CrossRef
68.
Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear-kappa B. Diabetes. 2001;50:2792–808.PubMedCrossRef
69.
Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation endproducts (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6:7–14.PubMedCrossRef
70.
Zhang Y, Papasian CJ, Deng HW. Alterations of vitamin D metabolic enzyme expression and calcium transporter abundance in kidney involved in type 1 diabetes-induced bone loss. Osteoporos Int. 2011;22:1781–8.PubMedCrossRef
71.
Bronsky J, Prusa R. Amylin fasting plasma levels are decreased in patients with osteoporosis. Osteoporos Int. 2004;15:243–7.PubMedCrossRef
72.
Horcajada-Molteni MN, Chanteranne B, Lebecque P, et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res. 2001;16:958–65.PubMedCrossRef
73.
Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone via the sympathetic nervous system. Cell. 2002;111:305–17.PubMedCrossRef
74.
75.
Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100:197–207.PubMedCrossRef
76.
77.
Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010;11:11–22.PubMedCrossRef
Metadata
Title
Diabetes Mellitus and Osteoporosis
Authors
Robert Sealand
Christie Razavi
Robert A. Adler
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 3/2013
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-013-0376-x

Other articles of this Issue 3/2013

Current Diabetes Reports 3/2013 Go to the issue

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Do Statins Cause Diabetes?

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Vascular Calcification in Diabetes: Mechanisms and Implications

Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes Mellitus and Inflammation

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Exercise and Diabetes-Related Cardiovascular Disease: Systematic Review of Published Evidence from Observational Studies and Clinical Trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits